Plasma DNA — mostly cell-free DNA (cfDNA) circulating outside of cells — is hard to extract because it exists at extremely low concentrations, breaks down into short fragments, and gets diluted or contaminated by DNA leaking out of white blood cells during sample handling. These combined factors make it easy to lose during purification and difficult to detect afterward, even with a successful extraction.
Low Starting Concentration
The core challenge is scarcity. Cell-free DNA concentration in plasma averages around 30 ng/mL, ranging from roughly 1.8 to 44 ng/mL in healthy people, which is a tiny amount compared to the DNA yield from whole blood cells. Cancer patients tend to have more, but even elevated concentrations up to around 180 ng/mL remain difficult to detect reliably.
This scarcity means any inefficiency in the extraction process — DNA sticking to tubes, incomplete binding to a column or magnetic bead, small pipetting losses — has an outsized effect on the final yield. Incomplete recovery during extraction can cause the loss of the specific fragments researchers are trying to detect, which then degrades downstream PCR or sequencing results.
Fragment Size and Fragility
Unlike genomic DNA extracted directly from cells, cfDNA circulates as short, already-fragmented pieces — typically around the length of DNA wrapped once around a nucleosome. This small size makes it harder to isolate cleanly with methods originally designed for long, intact genomic DNA strands, and it’s easier for these fragments to be lost or degraded during processing.
Contamination From White Blood Cells
A major practical problem is separating the plasma cfDNA researchers actually want from genomic DNA released by white blood cells during blood collection and processing. Researchers analyzing circulating tumor DNA face two major issues: contamination from white blood cell genomic DNA, and the low overall amount of circulating DNA itself.
This contamination risk is why sample handling timing matters so much. Whole blood needs to be centrifuged within about an hour of collection to remove blood cells, and the resulting plasma is then centrifuged again at a much higher force to clear out any remaining cellular material before DNA extraction. If white blood cells break down before this separation happens, they release their own genomic DNA into the plasma, swamping the much smaller amount of true cell-free DNA.
Detecting Rare Targets Within cfDNA
For clinical applications like cancer monitoring, the difficulty compounds further. Circulating tumor DNA is often less than 0.01% of the total cfDNA present in a sample, meaning the DNA of actual clinical interest is a tiny fraction of an already scarce material. Extraction methods have to preserve that rare signal without losing it in the process, which is harder than simply maximizing total DNA yield.
Extraction Method Matters
Different extraction kits produce meaningfully different results. A comparison of extraction kits found up to a 4.3-fold difference in DNA yield between methods, with spin-column and automated magnetic bead approaches performing best for reproducibility. Because preanalytical handling factors significantly affect both the quality and quantity of recovered cfDNA, labs need to standardize collection and processing steps carefully rather than assuming any kit or protocol will perform the same way.
Special Case: DNA From Old Plasma Tubes
A related but distinct problem arises when researchers need genomic DNA — not cfDNA — from blood that was originally collected in plasma-specific tubes rather than standard DNA-collection tubes. Recovering DNA from clotted blood in older plasma tubes has been difficult mainly because of the gel separator these tubes contain, which obstructs clot extraction and complicates dispersing the clot. This is a separate challenge from cfDNA extraction, but it reflects the same underlying theme: plasma-based samples are collected and preserved for purposes other than DNA analysis, so extracting usable DNA from them often means working against the sample’s original design.
Join The Discussion
If you’ve worked with plasma DNA extraction in a lab setting, what techniques or kits have you found actually improve yield or reduce contamination in practice?
